HRT Financial’s Protalix BioTherapeutics PLX Stock Holding History

HRT Financial’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-64,610	Closed	-$116K	–	4522
2025 Q4	$116K	Buy	+64,610	New	+$132K	﹤0.01%	2761
2024 Q3	–	Sell	-80,224	Closed	-$93K	–	2973
2024 Q2	$93K	Buy	+80,224	New	+$94.8K	﹤0.01%	1772
2023 Q2	–	Sell	-10,309	Closed	-$21K	–	3088
2023 Q1	$21K	Buy	+10,309	New	+$18.1K	﹤0.01%	2180

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

HRT Financial's PLX Position: Q1 2026 in Review

HRT Financial sold out of Protalix BioTherapeutics (PLX) in Q1 2026, closing a stake of 64,610 shares — an estimated $116K sold.

HRT Financial first reported a position in PLX in Q1 2023 and held it in 3 quarters. The position peaked at $116K in Q4 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

HRT Financial reported no remaining Protalix BioTherapeutics position as of Q1 2026 after selling out during the quarter.
HRT Financial sold 64,610 Protalix BioTherapeutics shares in Q1 2026, an estimated $116K.
HRT Financial first reported a position in Protalix BioTherapeutics in Q1 2023 and held it in 3 quarters.
HRT Financial's Protalix BioTherapeutics position peaked at $116K in Q4 2025.
99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.